1 / 9

Analysis of Patient Enrollment and Efficacy Parameters in the SAGE Study

This study delves into the baseline characteristics of patients enrolled in the SAGE study, examining myocardial ischemia duration, lipid parameter changes, primary and secondary efficacy parameters, time to MACE and all-cause death, and overall safety results. The summary provides a comprehensive overview of the study's findings at 12 months.

marsden-case
Download Presentation

Analysis of Patient Enrollment and Efficacy Parameters in the SAGE Study

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Patient enrollment in SAGE Prakash Deedwania, et al. Circulation 2007;115:700-707

  2. Baseline Characteristics of Patients Randomized in the SAGE Study Prakash Deedwania, et al. Circulation 2007;115:700-707

  3. Mean total duration of myocardial ischemia over 48 hours at baseline, month 3, and month 12 in the modified intent-to-treat population Prakash Deedwania, et al. Circulation 2007;115:700-707

  4. Least-squares mean percent changes in lipid parameters from baseline Prakash Deedwania, et al. Circulation 2007;115:700-707

  5. Summary of Results for Primary Efficacy Parameters and Secondary Efficacy Parameters at Month 12 Prakash Deedwania, et al. Circulation 2007;115:700-707

  6. Kaplan-Meier plot for the time to the first MACE end point up to month 12. *At risk at month 12 plus 8 days Prakash Deedwania, et al. Circulation 2007;115:700-707

  7. Kaplan-Meier estimates of time to all-cause death during the 12-month treatment period. *At risk at month 12 plus 8 days Prakash Deedwania, et al. Circulation 2007;115:700-707

  8. Summary of MACE During the SAGE Study Prakash Deedwania, et al. Circulation 2007;115:700-707

  9. Summary of All-Cause Safety Results Prakash Deedwania, et al. Circulation 2007;115:700-707

More Related